An enhanced activity of receptor tyrosine kinases (RTKs), such as the platelet-derived growth factor (PDGF) α-receptor (PDGF-Rα) or the PDGF β-receptor (PDGF-Rβ), is involved in the development of proliferative diseases. We have previously demonstrated that green tea catechins containing a galloyl group in the third position of the catechin structure interfere with PDGF-BBinduced mitogenic signaling pathways by inhibiting tyrosine phosphorylation of the PDGF-Rβ. However, the underlying cellular and molecular mechanisms are unknown. Using human vascular smooth muscle cells (VSMC) and porcine endothelial cells (AEC) stably transfected with PDGF-Rα and -β, respectively, we demonstrate that EGCG preferably inhibited PDGF-BB isoform-mediated signal transduction pathways and cell proliferation. To elucidate cellular and molecular mechanisms of the inhibitory effects of EGCG, we studied the distribution of incorporated EGCG into cellular compartments after subcellular fractionation. Interestingly, most (85%) of the EGCG was found in the cytoplasmic fraction, whereas only ~2% was found within the cell plasma membranes. However, no alteration of membrane fluidity has been observed after treatment of VSMC with 50 µM EGCG. n enhanced activity of the receptor tyrosine kinases (RTKs) such as the platelet-derived growth factor (PDGF) α-receptor (PDGF-Rα) and the β-receptor (PDGF-Rβ) contribute A to the development of proliferative diseases such as tumor and atherosclerosis (1-4). PDGF is a dimeric protein composed of A-and B-chains. The A-and B-chain are able to form three isoforms: PDGF-AA, PDGF-BB, and PDGF-AB. All three isoforms bind with high affinity to the PDGF-Rα, whereas only PDGF-BB binds with high affinity to PDGF-Rβ (5). PDGF-Rα and PDGF-Rβ propagate mitogenic signals through ligand-induced receptor autophosphorylation. Tyrosine-phosphorylated PDGF-Rα or PDGF-Rβ induce tyrosine-phosphorylation of different substrate proteins, including phospholipase C-γ1 (PLC-γ1), phosphatidylinositol 3′-kinase (PI 3′-K), and extracellular response kinases 1/2 (ERK1/2) via the p21 ras /mitogen-activated protein kinase kinase (MEK) pathway (5, 6). Activation of PLC-γ1 results in hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP 2 ) to diacylglycerol (DG) and IP 3 , which triggers the release of Ca 2+ from endoplasmic reticulum (ER) (5, 7).
to the development of proliferative diseases such as tumor and atherosclerosis (1) (2) (3) (4) . PDGF is a dimeric protein composed of A-and B-chains. The A-and B-chain are able to form three isoforms: PDGF-AA, PDGF-BB, and PDGF-AB. All three isoforms bind with high affinity to the PDGF-Rα, whereas only PDGF-BB binds with high affinity to PDGF-Rβ (5) . PDGF-Rα and PDGF-Rβ propagate mitogenic signals through ligand-induced receptor autophosphorylation. Tyrosine-phosphorylated PDGF-Rα or PDGF-Rβ induce tyrosine-phosphorylation of different substrate proteins, including phospholipase C-γ1 (PLC-γ1), phosphatidylinositol 3′-kinase (PI 3′-K), and extracellular response kinases 1/2 (ERK1/2) via the p21 ras /mitogen-activated protein kinase kinase (MEK) pathway (5, 6) . Activation of PLC-γ1 results in hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP 2 ) to diacylglycerol (DG) and IP 3 , which triggers the release of Ca 2+ from endoplasmic reticulum (ER) (5, 7) .
We have previously demonstrated that green tea catechins interfere with PDGF-induced mitogenic signaling pathways. For example, catechins with a galloyl group in the 3-position of the catechin structure, such as epigallocatechin-3 gallate (EGCG), epicatechin-3 gallate (ECG), and catechin-3 gallate (CG) are able to suppress the PDGF-BB-induced stimulation of the PDGF-Rβ-mediated signal transduction pathway in rat and human vascular smooth muscle cells (VSMC) as well as in human A172 glioblastoma cells (7) (8) (9) . In contrast, catechin compounds without a galloyl group, such as catechin and epicatechin (EC), had no effect on PDGF-Rβ signal transduction pathways in rat and human VSMC (8) as well as in A172 cells (9) . Furthermore, we showed that spheroid formation of A172 cells and colony formation of sistransfected NIH 3T3 cells in semisolid agar were completely inhibited by EGCG (8, 9) . Importantly, EGCG treatment inhibited neointima formation in a rat carotid artery injury model (8) .
In this study, the molecular mechanisms of the inhibitory effects of EGCG on PDGF-induced cell signaling and mitogenesis were investigated. Using human VSMC and porcine endothelial cells (AEC) stably transfected with PDGF-Rα and -β, respectively, we demonstrate that EGCG preferrably inhibited PDGF-BB isoform-mediated signal transduction pathways and cell proliferation. Several lines of evidence are presented for a mechanism, involving an incorporation of EGCG into different cellular compartments, including cell surface membranes, which leads to a nondisplaceable binding of PDGF to non-receptor binding sites, resulting in a reduced PDGF binding to the respective receptors.
MATERIALS AND METHODS

Materials
PDGF-BB was a gift from Jürgen Hoppe (University of Würzburg, Germany) and was prepared as described previously (10) . Monoclonal mouse anti-PI 3′-K and mouse anti-PLC-γ1 mouse antibodies were obtained from Transduction Laboratories (Lexington, KY). Rabbit polyclonal antibodies against PDGF-Rα, PDGF-Rβ, and phospho-PDGF-Rβ were from Santa Cruz (Heidelberg, Germany 
Cell culture
Human VSMC were obtained from Bio Whittaker Europe (Verviers, Belgium) and were cultured in smooth muscle medium containing 5% fetal calf serum (FCS). For some experiments, rat VSMC were used (12) . Porcine aortic endothelial cells (AEC) expressing wild types PDGF-Rα and PDGF-Rβ were kindly provided by Lena Claesson-Welsh and Carl-Henrik Heldin (Uppsala University, Sweden). AEC were cultured in Ham's F12 medium supplemented with 10% FCS.
Cell stimulation
Cells at ~70% confluency were preincubated for 24 h with EGCG or vehicle in DMEM/Ham's F-10 (1:1, v/v) containing 0.4% FCS (starvation medium). Then the medium was replaced with starvation medium without EGCG and cells were stimulated with different PDGF isoforms (50 ng/ml) for different time periods.
Immunoprecipitation, gel electrophoresis, and Western blot analysis
After stimulation, cells were lyzed with 1 ml RIPA buffer (50 mM NaCl, 20 mM Tris-HCl, 50 mM NaF, 10 mM EDTA, 20 mM Na 4 P 2 O 7 , 1% Triton X-100, pH 7.4) containing 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 µg/ml leupeptin, 10 µg/ml antipain, and 0.023 TIU/ml aprotinin. Tyrosine-phosphorylated proteins were immunoprecipitated as described previously (8) using agarose-coupled anti-phosphotyrosine antibodies. For immunodetection, proteins were separated and probed with anti-PI 3′-K (1:5000), anti-PLC-γ1 (1:1000), anti-PDGF-Rα (1:500), or anti-phospho-PDGR-Rβ (1:500) andibodies followed by the appropriate secondary antibodies. Bands were detected by enhanced chemiluminescence. Densitometric analysis was performed using a calibrated scanner densitometer (GS-800, Bio-Rad, Munich, Germany).
Measurement of [Ca
2+
] i
Cells were cultured on round glass microscope slides (diameter, 12 mm) under normal tissue culture conditions until 70% confluency. [Ca 2+ ] i transients were measured as described previously (8) .
Determination of cell counts
For cell counting, cells were seeded in 24-well culture plates (5×10 4 cells/well) and cultured at 37°C for 24 h. The medium was then replaced by DMEM and Ham's F-10 (1:1, vol/vol) containing 0.4% FCS and catechins. After 24 h, the medium was replaced with starvation medium, and cells were stimulated with different PDGF isoforms (50 ng/ml). After another 24 h, the cells were trypsinized and counted using the CASY-1 system (Schärfe, Reutlingen, Germany) as described previously (11) .
Incorporation of ECGC into human VSMC
Human VSMC were seeded in 24-well culture plates (5×10 4 cells/well) and cultured at 37°C for 24 h. The cells were then incubated with 50 µM EGCG and 1 µCi [
3 H]-EGCG (5 Ci/mmol) for different time periods. Experiments were terminated by removing the supernatant and subjecting the cultures to three sequential washes with PBS. Cells were lyzed with 0.5 M NaOH, and [
3 H]-EGCG was quantified using a liquid scintillation counter (Beckman LS 3801, Düsseldorf, Germany). In additional experiments, the incorporation of [ 3 H]-EGCG was measured in subcellular plasma and intracellular membrane fractions, which were generated as previously described (12) . The morphology of EGCG-treated human VSMC was studied after hematoxylin eosin stain (BX50, Olympus, Hamburg, Germany).
Membrane fluidity
The effects of EGCG on membrane fluidity were determined by measuring fluorescence anisotropy of the lipid soluble fluorophore diphenylhexatriene (DPH) using a variable temperature fluorescence polarization system (Beacon 2000, Panvera, Madison, MI) as described previously (12) . ]-PDGF-BB binding studies were performed as described previously (13) . In brief, confluent rat VSMC in 24-well culture plates were preincubated in starvation medium in the presence and absence of 50 µM EGCG for 24 h. Then cell monolayers were rinsed twice with PBS, and medium was replaced with starvation medium. After 1 h at 37°C, cells were incubated with 5 ng/ml [ 125 I]-PDGF-BB (800 Ci/mmol) in the presence and absence of different concentrations of unlabeled PDGF-BB for 30 min. Cells were then chilled on ice and washed three times with PBS containing 0.25% bovine serum albumin. Then cells were solubilized with 500 µl 0.5 N NaOH, and γ-radiation was quantified as described previously (13) .
Statistics
Data are expressed as the arithmetic mean ± SD. Statistical analysis was performed using the Mann-Whitney U test. P < 0.05 was considered statistically significant.
RESULTS
Effects of EGCG on PDGF-AA-and PDGF-BB-induced tyrosine-phosphorylation of PDGF-Rα, PLC-γ1, and mitogenesis of human VSMC
In human VSMC, EGCG (50 µM) almost completely (85±6%, n=3) inhibited PDGF-BB-induced phosphorylation of PDGF-Rα. Only a partial (25±5%, n=3) inhibition of receptor phosphorylation was observed upon stimulation with PDGF-AA (Fig. 1A) . As described previously for the PDGF-Rβ phosphorylation, ECG also inhibited phosphorylation of PDGF-Rα whereas EC was not effective (data not shown). In agreement with these findings, EGCG completely inhibited PDGF-BB-induced cell proliferation. PDGF-AA-induced cell proliferation was only inhibited by ~50% (Fig. 1B) .
Effects of EGCG on PDGF-induced signal transduction pathway in porcine AEC expressing PDGF-Rα or PDGF-Rβ
The experiments presented thus far indicate some specificity of EGCG for the effects of PDGF-BB as compared with the PDGF-AA isoform. Thus, experiments were carried out with porcine aortic endothelial cells (AEC) stably transfected with either PDGF-Rα or PDGF-Rβ.
In porcine AEC expressing PDGF-Rα, EGCG had no effects on the PDGF-AA-or PDGF-ABinduced tyrosine-phosphorylation of the PDGF-Rα (Fig. 2A) . Similarly, EGCG did not inhibit phosphorylation of PDGF-AA-or PDGF-AB-induced phosphorylation of PLC-γ1 ( Fig. 2A) or of ERK-1/2 (data not shown). However, PDGF-BB-induced phosphorylation of PDGF-Rα, PLC-γ1 ( Fig. 2A) , or ERK-1/2 (data not shown) was concentration-dependently inhibited by EGCG. In addition, EGCG did not affect PDGF-AA-induced increase in [Ca 2+ ] i but markedly (60%) inhibited PDGF-BB-induced [Ca 2+ ] i signals (Fig. 2B) . Interestingly, EGCG inhibited the mitogenic effects of PDGF-AA and -AB by 50%. However, PDGF-BB-induced mitogenesis was almost completely blocked by EGCG (Fig. 2C) .
In porcine AEC expressing PDGF-Rβ, PDGF-AA had no effect on tyrosine phosphorylation of PDGF-Rβ (Fig. 3A) . PDGR-Rβ phosphorylation induced by PDGF-AB or -BB was inhibited (50-60%) by EGCG. Similar findings were obtained for phosphorylation of PLC-γ1 (Fig. 3A) . In addition, a marked (50%) inhibition of PDGF-BB-induced [Ca 2+ ] i transients by EGCG was observed (Fig. 3B) . Consistently, PDGF-AA did not stimulate mitogenesis of PDGF-Rβ-expressing porcine AEC. PDGF-AB-or -BB-induced cell proliferation was completely inhibited by EGCG in this cell system (Fig. 3C) .
Mechanisms of the inhibitory effects of EGCG on PDGF-BB-induced signaling and mitogenesis in human VSMC
In our experiments, EGCG was incubated with the cells for 24 h, and the EGCG-containing medium was removed before stimulation with PDGF. Thus, a competitive inhibition of PDGF binding to the receptor is not a likely mechanism for the inhibitory effects of the compound, as described in our study. This is further supported by data demonstrating that the inhibition of PDGF-BB-induced PDGF-Rβ phosphorylation by EGCG could not be overcome by increasing the concentrations of PDGF up to 1000 ng/ml (Fig. 4) .
To gain insights into the mechanisms of the inhibitory effects of EGCG, possible cellular incorporation of EGCG was determined using [
3 H]-labeled EGCG. These experiments demonstrated a time-dependent incorporation of EGCG into human VSMC with maximal enrichment after 14 h (Fig. 5A ). In addition, the distribution of incorporated EGCG within cellular compartments, including plasma and mitochondrial membranes was studied after subcellular fractionation. Interestingly, most (85%) of the EGCG was found in the cytoplasmic fraction, whereas only ~2% was found within the cell surface membranes (Fig. 5B) .
However, because EGCG inhibits very early events of PDGF signaling (i.e., receptor autophosphorylation) and because morphological analysis revealed that most of the cytoplasmic EGCG probably was stored in inclusion bodies (Fig. 5C) , it was conceivable to study possible mechanisms "located" at the cell surface membrane.
We have previously shown that an alteration of membrane fluidity, as observed in cholesterolenriched cells, may alter PDGF-mediated signaling and mitogenesis (12) . Thus, possible effects of EGCG on membrane fluidity were studied. However, as determined by the measurement of DPH fluorescence anisotropy, EGCG did not change the fluidity of human VSMC membranes (Fig. 6A) . Because the inhibition of PDGF-induced PDGF-Rβ phosphorylation was insurmountable, a possible reduction of specific PDGF-BB binding sites was studied in a ligand binding experiments, using rat VSMC. In control cells, the specific binding of [
125 I]-PDGF-BB, as determined by displacement with 50-fold excess of unlabeled PDGF-BB, amounted to ~60% (Fig. 6B) . From these data, a K d value of 300 pM consistent with literature data (14) 125 I]-PDGF-BB was incubated with VSMC in the presence of EGCG, a significant reduction of cellular PDGF-BB binding was observed (Fig. 6C) , indicating a direct interaction between EGCG and PDGF-BB.
DISCUSSION
Antiproliferative effects of green tea catechins are well known and have been, at least partially, explained by antioxidative actions of the compounds (15) . We have previously shown that catechins with a galloyl group in the 3-position of the catechin structure, such as ECG, CG, and EGCG, are able to suppress the PDGF-BB-induced stimulation of the PDGF-Rβ-mediated signal transduction pathways and mitogenesis of VSMC (8).
This study is the first to propose a mechanism for the antiproliferative effects of EGCG. Evidence is presented for a mechanism, involving an incorporation of EGCG into different cellular compartments, including cell surface membranes, that leads to a nondisplaceable binding of PDGF to non-receptor binding sites, most likely resulting in a reduced PDGF binding to the respective receptors.
Although only ~2% of the incorporated EGCG was found in cell surface membranes, several lines of evidence favor a surface-membrane-linked mechanism of action of this catechin: Morphological analysis of EGCG-treated human VSMC revealed that most of the cytoplasmic EGCG was stored in vesicle-like inclusion bodies. Thus EGCG incorporated into these structures is not likely to inhibit PDGF-R kinase or other signaling molecules. In addition, the inhibitory actions of EGCG occur at a very early step in the PDGF signal transduction, namely at the site of PDGF-R autophosphorylation. Finally, ligand binding studies demonstrated a nondisplaceable binding of PDGF to non-receptor binding sites on EGCG-treated VSMC.
It has been shown that phospholipid membrane bilayers can incorporate EGCG, resulting in a disruption of membrane structure and in an inhibition of protein kinase C (PKC) (16) . However, in our studies, treatment with EGCG did not result in a nonspecific alteration of physical membrane properties, as examplified by the measurement of membrane fluidity. Thus, a more specific mechanism should explain the antiproliferative effects of EGCG.
In fact, in a separate series of experiments a direct interaction between EGCG and PDGF-BB could be demonstrated. Although a direct binding of soluble EGCG with PDGF-BB does not explain the inhibitory effects in our study because cell stimulation was performed in the absence of EGCG, a "trapping" of PDGF by EGCG, incorporated into the plasma membrane, might have prevented specific binding of PDGF-BB to its respective receptors. This molecular action mode of EGCG provides an attractive model to explain the antiproliferative actions catechins (Fig. 7) .
In this context, note that catechins not only bind to PDGF but also are able to interact with several other proliferation-related proteins (16) (17) (18) (19) (20) (21) (22) (23) . Furthermore, a binding of PDGF to membrane components, such as gangliosides GM1 or GM2, has been reported (13) . These gangliosides have also been shown to bind to other growth factors, such as basic fibroblast growth factor (bFGF) (24) . Thus, a "trapping" of growth factors by non-receptor binding sites may represent a general principle in modulation of growth factor activity.
Another interesting aspect of our study is the demonstration of a preferable inhibition of PDGF-BB-as compared with PDGF-AA-induced cell signaling and mitogenesis. Some specificity for PDGF-BB was observed in human VSMC. For example, EGCG only partially inhibited PDGF-AA-induced phosphorylation of PDGF-Rα, as opposed to an almost complete inhibition of PDGF-BB-induced receptor phosphorylation. This apparent selectivity was supported by experiments with porcine AEC stably transfected with PDGF-Rα. In these cells, EGCG did not inhibit PDGF-AA-induced phosphorylation of PDGF-Rα, PLC-γ1, or ERK-1/2. Similarly, PDGF-AA-induced [Ca 2+ ] i transients were not affected by EGCG. In contrast, EGCG markedly inhibited PDGF-BB-induced receptor phosphorylation and intracellular signaling events. In porcine AEC stably transfected with PDGF-Rβ, EGCG inhibited both PDGF-BB-and PDGF-AB-induced phosphorylation of PDGF-Rβ and PLC-γ1. Thus, the specificity of the inhibitory effects of EGCG for the PDGF-BB-induced cell signaling is not absolute and not necessarily restricted to PDGF. In fact, data from our group demonstrated an inhibition of vascular endothelial cell factor (VEGF)-induced cell signaling by EGCG (Neuhaus et al., unpublished results).
Some degree of specificity for the PDGF-BB isoform was also observed for the inhibition of cell proliferation by EGCG. Although more pronounced effects were seen with PDGF-BB as a stimulus, cell proliferation induced by any PDGF isoform was inhibited by EGCG. Furthermore, in PDGF-Rα-transfected porcine AEC, EGCG significantly inhibited PDGF-AA-induced mitogenesis without affecting PDGF-AA-induced signaling events (phosphorylation of PDGF-Rα and of PLC-γ1, [Ca 2+ ] i transients). Thus, the inhibitory effect of EGCG must be mediated by additional mechanisms independent of the early signal transduction pathway of the PDGF-Rα, for example, by modulation of the expression/activity of cell cycle components.
Recently, tremendous efforts have been made to develop synthetic receptor tyrosine kinase (RTK) inhibitors as drug targets for therapy of cancer and cardiovascular diseases (15, 25, 26) . In this context, there are currently a large number of small-molecule RTK antagonists directed to PDGF-R, EGF-R, and VEGF-R (26) in phase I-III clinical development stages (27) . The mechanism of the inhibitory actions of EGCG, as proposed in the present study, may help to better understand the beneficial effects of catechins in human epidemiological studies and in animal atheroscleosis models. The noncompetitive inhibition of PDGF-induced mitogenesis by EGCG incorporated into cell membranes, in addition to direct binding of PDGF (and possibly other growth factors), would result in a sustained inhibition of cell proliferation even at low plasma concentrations between doses. Thus, EGCG or other galloyl group-containing plantderived catechins are attractive candidates to treat proliferative diseases. Human VSMC were stimulated with 3-1000 ng/ml PDGF-BB for 5 min. Tyrosine-phosphorylated PDGF-Rβ (~180 kDa) was detected by Western blotting. Original Western blot (A); densitometric analysis (means means ± SD, n=2) (B). 3 H]-EGCG in the presence of 50 µM unlabeled EGCG for 24 h. After subcellular fractionation, radioactivity was measured in the cytoplasmic (C) and membrane (M) fraction. Membranes were further fractionated into intracellular (Mi) and cell surface (Ms) membranes. Data are means ± SD; n = 2. C) Human VSMC were incubated with 50 µM unlabeled EGCG for 24 h. Cells were fixed with methanol, and microscopic analysis was performed after hematoxylin-eosin stain. 
